76 related articles for article (PubMed ID: 20123124)
21. Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites.
Schupp M; Lee LD; Frost N; Umbreen S; Schmidt B; Unger T; Kintscher U
Hypertension; 2006 Mar; 47(3):586-9. PubMed ID: 16365190
[TBL] [Abstract][Full Text] [Related]
22. PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine.
Davies EJ; Marsh Durban V; Meniel V; Williams GT; Clarke AR
J Pathol; 2014 May; 233(1):27-38. PubMed ID: 24293351
[TBL] [Abstract][Full Text] [Related]
23. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
24. Altered promoter recycling rates contribute to dominant-negative activity of human peroxisome proliferator-activated receptor-gamma mutations associated with diabetes.
Li G; Leff T
Mol Endocrinol; 2007 Apr; 21(4):857-64. PubMed ID: 17227883
[TBL] [Abstract][Full Text] [Related]
25. 3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation.
Yin Y; Yuan H; Wang C; Pattabiraman N; Rao M; Pestell RG; Glazer RI
Mol Endocrinol; 2006 Feb; 20(2):268-78. PubMed ID: 16150867
[TBL] [Abstract][Full Text] [Related]
26. Isolation and characterization of a transcriptional cofactor and its novel isoform that bind the deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
Tomaru T; Satoh T; Yoshino S; Ishizuka T; Hashimoto K; Monden T; Yamada M; Mori M
Endocrinology; 2006 Jan; 147(1):377-88. PubMed ID: 16239304
[TBL] [Abstract][Full Text] [Related]
27. Cyclin D3 promotes adipogenesis through activation of peroxisome proliferator-activated receptor gamma.
Sarruf DA; Iankova I; Abella A; Assou S; Miard S; Fajas L
Mol Cell Biol; 2005 Nov; 25(22):9985-95. PubMed ID: 16260612
[TBL] [Abstract][Full Text] [Related]
28. Cysteine at position 217 in the intracellular loop 1 plays a critical role in human PTH receptor type 1 membrane translocation and function.
Thomas BE; Wittelsberger A; Woznica I; Hsieh MY; Monaghan P; Lee BK; Rosenblatt M
J Bone Miner Res; 2007 Apr; 22(4):609-16. PubMed ID: 17227205
[TBL] [Abstract][Full Text] [Related]
29. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
30. Caspase-1 is a direct target gene of ETS1 and plays a role in ETS1-induced apoptosis.
Pei H; Li C; Adereth Y; Hsu T; Watson DK; Li R
Cancer Res; 2005 Aug; 65(16):7205-13. PubMed ID: 16103071
[TBL] [Abstract][Full Text] [Related]
31. Rational discovery of a novel interface for a coactivator in the peroxisome proliferator-activated receptor gamma: theoretical implications of impairment in type 2 diabetes mellitus.
Shiraki T; Kodama TS; Jingami H; Kamiya N
Proteins; 2005 Feb; 58(2):418-25. PubMed ID: 15558556
[TBL] [Abstract][Full Text] [Related]
32. Single gene contributions: genetic variants of peroxisome proliferator-activated receptor (isoforms alpha, beta/delta and gamma) and mechanisms of dyslipidemias.
Yong EL; Li J; Liu MH
Curr Opin Lipidol; 2008 Apr; 19(2):106-12. PubMed ID: 18388689
[TBL] [Abstract][Full Text] [Related]
33. Mutation cluster region, association between germline and somatic mutations and genotype-phenotype correlation in upper gastrointestinal familial adenomatous polyposis.
Groves C; Lamlum H; Crabtree M; Williamson J; Taylor C; Bass S; Cuthbert-Heavens D; Hodgson S; Phillips R; Tomlinson I
Am J Pathol; 2002 Jun; 160(6):2055-61. PubMed ID: 12057910
[TBL] [Abstract][Full Text] [Related]
34. Identification of the first germline mutation in the extracellular domain of the follitropin receptor responsible for spontaneous ovarian hyperstimulation syndrome.
De Leener A; Caltabiano G; Erkan S; Idil M; Vassart G; Pardo L; Costagliola S
Hum Mutat; 2008 Jan; 29(1):91-8. PubMed ID: 17721928
[TBL] [Abstract][Full Text] [Related]
35. A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes.
Sakamoto J; Kimura H; Moriyama S; Imoto H; Momose Y; Odaka H; Sawada H
Eur J Pharmacol; 2004 Jul; 495(1):17-26. PubMed ID: 15219816
[TBL] [Abstract][Full Text] [Related]
36. A disulfide bonding interaction role for cysteines in the extracellular domain of the thyrotropin-releasing hormone receptor.
Cook JV; McGregor A; Lee T; Milligan G; Eidne KA
Endocrinology; 1996 Jul; 137(7):2851-8. PubMed ID: 8770906
[TBL] [Abstract][Full Text] [Related]
37. Dominant inheritance of adenomatous colonic polyps and colorectal cancer.
Burt RW; Bishop DT; Cannon LA; Dowdle MA; Lee RG; Skolnick MH
N Engl J Med; 1985 Jun; 312(24):1540-4. PubMed ID: 4000184
[TBL] [Abstract][Full Text] [Related]
38. STK11/LKB1 germline mutations in the first Peutz-Jeghers syndrome patients identified in Slovakia.
Bartosova Z; Zavodna K; Krivulcik T; Usak J; Mlkva I; Kruzliak T; Hromec J; Usakova V; Kopecka I; Veres P; Bartosova Z; Bujalkova M
Neoplasma; 2007; 54(2):101-7. PubMed ID: 17319781
[TBL] [Abstract][Full Text] [Related]
39. Manipulation of reciprocal salt bridges at the heterodimerization interface alters the dimerization properties of mouse RXRalpha and PPARgamma1.
Chan LS; Wells RA
Biochem Biophys Res Commun; 2007 Jul; 358(4):1080-5. PubMed ID: 17521607
[TBL] [Abstract][Full Text] [Related]
40. S 26948: a new specific peroxisome proliferator activated receptor gamma modulator with potent antidiabetes and antiatherogenic effects.
Carmona MC; Louche K; Lefebvre B; Pilon A; Hennuyer N; Audinot-Bouchez V; Fievet C; Torpier G; Formstecher P; Renard P; Lefebvre P; Dacquet C; Staels B; Casteilla L; Pénicaud L;
Diabetes; 2007 Nov; 56(11):2797-808. PubMed ID: 17704298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
